We are live on ! Find out more
THRN

Thorne Healthtech, Inc. Common Stock

Delisted

THRN was delisted on the 13th of October, 2023.

44 hedge funds and large institutions have $22.1M invested in Thorne Healthtech, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 20 increasing their positions, 10 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 10

28% more capital invested

Capital invested by funds: $17.3M → $22.1M (+$4.83M)

2% less funds holding

Funds holding: 4544 (-1)

13% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 8

Holders
44
Holders Change
-1
Holders Change %
-2.22%
% of All Funds
0.7%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
20
Reduced
10
Closed
8
Calls
$1K
Puts
Net Calls
+$1K
Net Calls Change
+$2K
Name Holding Trade Value Shares
Change
Change in
Stake
EA
1
Emerald Advisers
Pennsylvania
$4.85M -$39.8K -9,047 -0.9%
Vanguard Group
2
Vanguard Group
Pennsylvania
$3.96M -$42.7K -9,708 -1%
EMFAT
3
Emerald Mutual Fund Advisers Trust
Pennsylvania
$3.89M
BlackRock
4
BlackRock
New York
$2.68M +$91.7K +20,833 +4%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$1.13M +$97.6K +22,189 +10%
Bank of America
6
Bank of America
North Carolina
$740K -$279K -63,312 -28%
RA
7
Royce & Associates
New York
$620K +$591K +134,300 New
MA
8
MYDA Advisors
New York
$615K -$74.2K -16,856 -11%
State Street
9
State Street
Massachusetts
$551K +$5.28K +1,200 +1%
Northern Trust
10
Northern Trust
Illinois
$514K +$27.4K +6,226 +6%
BCM
11
Bridgeway Capital Management
Texas
$323K +$308K +69,900 New
Bank of New York Mellon
12
Bank of New York Mellon
New York
$301K
Dimensional Fund Advisors
13
Dimensional Fund Advisors
Texas
$254K +$143K +32,395 +144%
Morgan Stanley
14
Morgan Stanley
New York
$205K +$112K +25,533 +136%
Charles Schwab
15
Charles Schwab
California
$169K +$10.1K +2,304 +7%
HSBC Holdings
16
HSBC Holdings
United Kingdom
$134K -$23.6K -5,352 -17%
Royal Bank of Canada
17
Royal Bank of Canada
Ontario, Canada
$123K +$93K +21,123 +387%
SG Americas Securities
18
SG Americas Securities
New York
$122K +$14.1K +3,197 +14%
Citadel Advisors
19
Citadel Advisors
Florida
$89.9K +$14.2K +3,217 +20%
Susquehanna International Group
20
Susquehanna International Group
Pennsylvania
$82K +$78.1K +17,744 New
RhumbLine Advisers
21
RhumbLine Advisers
Massachusetts
$81K +$3.15K +716 +4%
Barclays
22
Barclays
United Kingdom
$63.6K +$15.3K +3,477 +34%
VF
23
Virtu Financial
New York
$62K +$4.45K +1,010 +8%
Renaissance Technologies
24
Renaissance Technologies
New York
$61K +$1.32K +300 +2%
Goldman Sachs
25
Goldman Sachs
New York
$57.6K -$65K -14,772 -54%

THRN Hedge Fund Activity: Q1 2023 in Review

44 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Thorne Healthtech, Inc. Common Stock (THRN) for Q1 2023, worth a combined $22.1M — up 28% from $17.3M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of THRN and 7 opened new positions — a net loss of 1 holder — while 10 trimmed existing stakes and 20 added.

The largest buyer was Royce & Associates, opening a new position worth an estimated $591K. The largest seller was Rockefeller Capital Management, exiting entirely with an estimated $298K sold.

  • 44 institutional investors held Thorne Healthtech, Inc. Common Stock (THRN) as of Q1 2023, down from 45 in Q4 2022.
  • Funds reported $22.1M of Thorne Healthtech, Inc. Common Stock stock for Q1 2023, up 28% quarter-over-quarter.
  • 7 funds opened new Thorne Healthtech, Inc. Common Stock positions in Q1 2023 and 8 closed out, a net change of -1 holder.
  • The largest Thorne Healthtech, Inc. Common Stock buyer in Q1 2023 was Royce & Associates, an estimated $591K added.
  • The largest Thorne Healthtech, Inc. Common Stock seller in Q1 2023 was Rockefeller Capital Management, an estimated $298K sold.

Based on aggregated 13F filings for Q1 2023.